EXOZ EXOZYMES INC.
Price Chart
Executive Summary
EXOZYMES INC. is raising approximately $4.7 million (before expenses) through a registered direct offering of 592,270 shares of common stock and 296,135 warrants, priced at $18.00 per unit (two shares + one warrant). The offering is dilutive (7% of shares outstanding) and the company explicitly warns it may not be able to continue as a going concern, with only $1.44M cash and a $23.5M accumulated deficit as of March 31, 2026. The underwriter MDB Capital has a conflict of interest as its parent owns 46.1% of EXOZ.
Actionable Insight
The offering is a dilutive capital raise by a pre-revenue biotech with a going-concern warning. The stock closed at $9.35, below the $9.00 per-share equivalent offering price, suggesting weak demand. Monitor for further dilution risk from the warrant reset provision and any subsequent capital needs.
Key Facts
- Offering of 592,270 shares (592,270 common + 296,135 warrants) at $18.00/unit, raising ~$4.7M net proceeds.
- Pro forma shares outstanding increase from 8,518,251 to 9,110,521 (~7% dilution).
- Net tangible book value per share is $0.18 pre-offering; new investors face $8.31 dilution per share.
- Cash and cash equivalents as of March 31, 2026: $1,444,562; accumulated deficit: $23,474,939.
- Company states it may not be able to continue as a going concern.
- Warrants have an exercise price reset to $0.001 if the company sells stock below the offering price within one year.
- Underwriter MDB Capital is a subsidiary of MDB Capital Holdings, which owns 46.1% of EXOZ pre-offering; FINRA conflict of interest declared.
- Stock closed at $9.35 on June 5, 2026, below the $9.00 per-share equivalent offering price.
Financial Impact
Dilution of ~7% of outstanding shares; net proceeds of ~$4.7M provide only short-term runway given $1.44M cash and ongoing losses.
Risk Factors
- Going-concern risk: company may not have sufficient liquidity to continue operations.
- Dilution from this offering and potential future offerings; warrant reset could cause massive dilution.
- No revenue; pre-commercialization stage with uncertain NCT product timeline.
- Conflict of interest with underwriter MDB Capital (parent owns 46.1%).
- Stock price already below offering price, indicating weak market reception.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-027611 |
| Document: 0001493152-26-027611-index-headers.html | 0001493152-26-027611 |
| Document: 0001493152-26-027611-index.html | 0001493152-26-027611 |
| Document: 0001493152-26-027611.txt | 0001493152-26-027611 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
8-K
| $9.00 awaiting T+1 | awaiting T+1 | — | $8.62 (+4.22%) |
|
Jun 8, 2026
1d ago
|
424B5
| $9.02 awaiting T+1 | awaiting T+1 | — | $8.62 (+4.43%) |
|
Jun 4, 2026
5d ago
|
424B5
| $9.35 $9.34 | ▲ +0.11% | ▼ −2.49% | $8.62 (+7.81%) |
|
May 29, 2026
11d ago
|
424B5
| $9.85 $9.67 | ▲ +1.78% | ▲ +2.04% | $8.62 (+12.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access